Amilo-5MER

N/A

Report date: 2022/01/18 14:59:26
NME

Base Information

Drug NameAmilo-5MER
Drug Alias NameAmilo-5MER
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionSerum amyloid A protein inhibitors
TargetsSerum amyloid A protein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)InflammationMultiple Sclerosis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe Hebrew University Of Jerusalem
China Registration ClassN/A

Develop Information

Active CompaniesGalmed Pharmaceuticals LtdThe Hebrew University Of Jerusalem
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)InflammationMultiple Sclerosis +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A